Clinical and prognostic significance of histamine monitoring in patients with CML during treatment with imatinib (STI571)

Annals of Oncology

Volumn 18, Issue 11, 2007, Pages 1834-1841

  Agis, H ^a   Sperr, W R ^a   Herndlhofer, S ^a   Semper, H ^a   Pirc Danoewinata, H ^b   Haas, O A ^b   Mannhalter, C ^a   Esterbauer, H ^a   Geissler, K ^c   Sillaber, C ^a   Jager U ^a   Valent, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^c Hietzing Hospital   (Austria)

Author keywords

Basophils; CML; Histamine; Imatinib; MRD

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; HISTAMINE; HYDROXYUREA; IMATINIB;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BASOPHIL; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOPENIA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HISTAMINE BLOOD LEVEL; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METAPHASE; MINIMAL RESIDUAL DISEASE; PATIENT MONITORING; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; RADIOIMMUNOASSAY; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; UPREGULATION;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HISTAMINE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASM, RESIDUAL; PIPERAZINES; PROBABILITY; PROGNOSIS; PYRIMIDINES; RADIOIMMUNOASSAY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 36248990259     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm343     Document Type: Article

References (29)

1. Faderl S, Tapaz M, Estrov Z. The biology of chronic myelogenous leukemia. N Eng J Med 1999; 341: 164-172.
2. Vardiman JW, Pierre R, Thiele J. Chronic myelogenous leukaemia, in Jaffe ES 1st ed. Tumours of Haematopoietic and Lymphoid Tissues, Pathology & Genetics, World Health Organization Classification of Tumors, Lyon: IRAC Press 2001; 20-26.
3. Sattler M, Griffin JD, Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 2003; 40: 4-10.
4. Sillaber C, Mayerhofer M, Agis H. Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts. Wien Klin Wochenschr 2003; 115: 485-504.
5. Gomez GA, Sokal JE, Walsh D. Prognostic features at diagnosis of chronic myelocytic leukemia. Cancer 1981; 47: 2470-2477.
6. Hasford J, Pfirrmann M, Hehlmann R et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90: 850-858.
7. Steegmann JL, Odriozola J, Rodriguez-Salvanes F et al. Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: The main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML. Haematologica 1999; 84: 978-987.
8. Gratwohl A, Hermans J, Niederwieser D. Bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 1993; 12: 509-516.
9. van Rhee F, Szydlo RM, Hermans J et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: A report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997; 20: 553-560.
10. Kantarjian HM, Smith TL, O'Brien S et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 1995; 122: 254-261.
11. Druker BJ, Talpaz M, Resta DJ. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
12. O'Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
13. Hughes TP, Kaeda J, Branford S et al. International Randomised Study of Interferon versus STI571 (IRIS) Study Group. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423-1432.
14. Talpaz M, Silver RT, Druker BJ et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 2002; 99: 1928-1937.
15. Druker BJ, Sawyers CL, Kantarjian H et al. Activity of specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042.
16. Sawyers CL, Hochhaus A, Feldman E et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood 2002; 99: 3530-3539.
17. Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to STI-571 cancer therapy caused by, BCR/ABL gene mutation or amplification. Science 2001; 2093: 2163.
18. Weisberg E, Griffin JD. Resistance to imatinib (Glivec): Update on clinical mechanisms. Drug Resist Updat 2003; 6: 231-238.
19. Goldman A Marin D, Olavarria E et al. Clinical decisions for chronic myeloid leukemia in the imatinib era. Semin Hematol 2003; 40: 98-103.
20. Hochhaus A, Reiter A, Skladny H et al. Molecular monitoring of residual disease in chronic myelogenous leukemia patients after therapy. Recent Results Cancer Res 1998; 144: 36-45.
21. Hughes T, Branford S. Molecular monitoring of chronic myeloid leukemia: Semin Hematol 2003; 40: 62-68.
22. Faderi S, Hochhaus A, Hugbes T. Monitoring of minimal residual disease in chronic myeloid leukemia. Hematol Oncol Clin North Am 2004; 18: 657-670,
23. O'Dwyer ME, Gatter KM, Loriaux M et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 2003; 17: 481-487.
24. Loriaux M, Deininger M. Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib. Leuk Lymphoma 2004; 45: 2197-2203.
25. Denburg JA, Wilson WE, Goodacre R et al. Chronic myeloid leukemia: evidence for basophil differentiation and histamine synthesis from cultured peripheral blood cells. Br J Haematol 1980; 45: 13-21.
26. Bettelheim P, Valent P. Radioimmunometric determination of histamine in myeloproliferative syndromes. Wien Klin Wochenschr 1989; 101: 706-10.
27. Bosma TJ, Kennedy MA, Bodger MP et al. Basophils exhibit rearrangement of the bcr gene in Philadelphia chromosome-positive chronic myeloid leukemia. Leukemia 1988; 2: 141-143.
28. Agis H, Beil WJ, Bankl HC et al. Mast cell lineage versus basophil lineage involvement in myeloproliferative and myelodysplastic syndromes: diagnostic role of cell-immunophenotyping. Leuk Lymphoma 1996; 22: 187-204.
29. Baccarani M, Saglio G, Goldman J et al. European LeukemiaNet. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809-1820.